# Savara Inc. (SVRA) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $4.75, market value $976 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Savara Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 3797.4×**. Each dollar of revenue is priced at 3797.4×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 8.4×**. The shares trade at 8.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -11.3%** (5-yr avg -13.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -58.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -19.5%**. Return on all capital, debt included, is -19.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -19.6%**. Each dollar of assets produces -19.6% of profit.

## Growth
- **EPS growth (1 yr): -10.4%**. Earnings per share fell 10.4%.

## Financial health
- **Debt to equity: 0.15**. Debt is 0.15 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.1×**. It would take 0.1 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: -0.0×**. Operating profit covers interest only -0.0×: fragile.
- **Current ratio: 11.85** (quick 11.85). Current assets cover the next year's liabilities 11.85 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Savara Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Savara Inc.; the consensus is strong_buy, with an average price target of $11.06 (+133% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 14.0%** (YTD -21.6%, 3-mo -11.3%). The shares are up 14.0% over twelve months including dividends.
- **From 52-week high: -32.2%** (23.1% above the low). Trading 32% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 1.40** (volatility 54%). Beta of 1.40 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SVRA · Page: https://foliofundamentals.com/stocks/svra

Not investment advice.